Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SABBOBCATon Oct 14, 2022 2:05pm
161 Views
Post# 35025316

RE:RE:New Corporate Presentation Out

RE:RE:New Corporate Presentation Out

Wow, i can't recall SPCEO being this close to packing it in before. Is this a puke on shoes moment beofre the rip, or is this a reality check that its time to get off the treadmill? Only time will tell.

 

jfm1330 wrote: Finally it was pointless to hope for something different. All we got was old Thera doing its usual stuff. This phase Ib is on track to be as much outside timelines given as the phase Ia was, which means late by a lot.

We can analyse what they say or don't say all we want, the reality is that we have no certainty about anything on real patients that can without a doubt link TH1902 to efficacy or proof of concept. They reiterated their 11% "level" of free docetaxel claim in the PR without specifying what this 11% clearly means. In this statement, "level" can mean different things depending on the nature of the measurement it is based on.

Honestly, it is incredible that 18 months after the start of the phase I we still cannot know for sure if the concept works and the whole trial is awfully slow. Maybe my expectations were not realistic, but if it's the case the whole trial process was very poorly explained by the company because since the fall of 2021 they were leading us to expect a great news on efficacy in a relatively near future, but this news never came and they are, again, pushing the timeframe. Maybe Levesque was blurting stuff in presentation without understanding what he was talking about, but the least I can say is that he was off marks since the beginning when he talked about timelines for this trial.

He talked often about how preclinical data about TH1902 was seen by outside people as "stunning". Then, all he said after that led to think that these "stunning" preclinical results would quickly lead to clear efficacy in humans and an easy proof of concept. 18 months after the start of the trial, we are down to very little. We are reduce to try to interpret stuff they say, their tone, participation to conferences or presentations, etc... but nothing of substance. Sorry, if they would have something of value in their hands, they would share it. They need it to raise money under acceptable terms. Honestly, I am close to giving up. Look at NASH, they went from very upbeat to close to zero, unwilling to declare the program dead. It now looks similar with TH1902. They still say all is on track, until the day they will tell us it's not. Also, why are they reassuring big investors in private after the conference call, while they are letting the little ones like me in the dark with the conference call? Anyway, if they did not disclose any new informations to these investors, how can they be reassured? Is the tone of the convesation again? That's what we are down to, looking at the tone of the CEO? Is he in a good day for BS or is he also tired of it? That's what we have left to decide to sell or not?




 

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse